Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones

Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the best high short interest stocks with biggest upside potential. On January 6, Mineralys Therapeutics announced the late 2025 filing of its NDA for lorundrostat. The company highlighted several clinical milestones, including the completion of three positive trials (Explore-CKD, Launch-HTN, and Advance-HTN), which demonstrated the drug’s 24-hour blood pressure control and safety across diverse patient populations. Additionally, Mineralys remains on track to report topline results from its Phase 2 Explore-OSA trial in Q1 2026 and continues to gather long-term data through its Transform-HTN open-label extension trial.

Earlier on December 19, Bank of America raised the firm’s price target on Mineralys Therapeutics to $46 from $43 with a Buy rating following the company’s Q3 2025 results and confirmed cash runway into 2027. BofA identified the acquisition of a commercialization and development partner as a major potential catalyst and viewed such a collaboration as necessary to maximize the value of the firm’s assets.

On the same day, Stifel also raised its price target on Mineralys Therapeutics Inc. (NASDAQ:MLYS) to $52 from $45 while keeping a Buy rating on the shares as part of a 2026 outlook note for the firm’s Biopharma coverage.

Mineralys Therapeutics Inc. (NASDAQ:MLYS) is a clinical-stage biopharmaceutical company that develops medicines to target diseases driven by dysregulated aldosterone in the US.

While we acknowledge the potential of MLYS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.